Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6874

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Renal Insufficiency, Chronic
Interventions: Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin, Placebo matching balcinrenone/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 68
States / cities: Huntsville, Alabama • Surprise, Arizona • Tempe, Arizona + 63 more

Conditions: Arthritis, Rheumatoid
Interventions: Tulisokibart, Placebo, Methotrexate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Glendale, Arizona • Mesa, Arizona • La Palma, California + 13 more

Conditions: Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more

Conditions: Aortic Stenosis
Interventions: Medtronic TAV, Edwards TAV; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: IgA Nephropathy
Interventions: TARPEYO®; Drug
Lead sponsor: Asahi Kasei Therapeutics, AB; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 37
States / cities: Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more

Conditions: Healthy Adult Participants
Interventions: Normal Stance, Inward Anchoring, Outward Anchoring; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 22
States / cities: Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more

Conditions: Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions: Muvalaplin, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 10,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 159
States / cities: Birmingham, Alabama • Apache Junction, Arizona • Gilbert, Arizona + 129 more

Conditions: Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
Interventions: Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 25 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 13
States / cities: Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more

Conditions: Cutaneous Melanoma
Interventions: Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Surveillance, Ultrasound Imaging, Wide Local Excision; Procedure · Other · Behavioral
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 75 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 181
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 142 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Vamorolone; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
Interventions: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks; Genetic
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2037
U.S. locations: 9
States / cities: Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

Mirikizumab Real World Protocol

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Anchoring and Postural Stability

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)